Can a consumer-grade bioimpedance device accurately estimate sarcopenia in women with type 2 diabetes? A cross-sectional agreement study with dual-energy X-ray absorptiometry
Authors' conclusion
The OMRON HBF-514C shows strong correlation, accurate diagnostic performance with optimized cut-offs, and minimal systematic bias after calibration. Its affordability, portability, and enhanced precision support its use for sarcopenia screening in resource-limited settings when combined with functional assessments.
Study context
- Population
- Women with T2D
- Participants
- 103 women
- Comparison
- Consumer-grade BIA vs DXA for detecting sarcopenia
- Outcome
- Diagnostic performance of BIA vs DXA for detecting sarcopenia
Performance
As reported in the abstract
Sarcopenia detection with optimized FFMI-BIA cut-offs (ROC analyses)
AUC (first ROC analysis)
0.878
Sensitivity/specificity (first ROC analysis)
87.8 %/79.3 %
AUC (second ROC analysis)
0.873
Sensitivity/specificity (second ROC analysis)
85.1 %/82.8 %
Further findings
Correlation of FFMI-BIA
- Correlation with FFMI-DXA (r)
- 0.881
- Correlation with skeletal muscle index (SMI) (r)
- 0.854
Bias-correction model
- Variance in FFMI-DXA explained
- 78.3 %
- Mean bias after correction
- −0.0009 kg/m²
- Limits of agreement
- −2.07 to 2.07 kg/m²
Agreement on sarcopenia classification
- Moderate agreement (κ)
- 0.575
Original publication
Can a consumer-grade bioimpedance device accurately estimate sarcopenia in women with type 2 diabetes? A cross-sectional agreement study with dual-energy X-ray absorptiometry. Diabetes Res Clin Pract. Published 21 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →